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Prazosin attenuates the natriuretic response to atrial natriuretic factor
in man. The effect of alpha-l-adrenoceptor blockade with 0.25 mg oral
prazosin on the renal response to atrial natriuretic factor (ANF) 5
pmol/kg/min was examined in eight healthy male volunteers undergoing
maximal water diuresis. ANF on its own decreased mean arterial blood
pressure (P < 0.05) without altering heart rate or increasing plasma
norepinephrine. ANF increased urinary sodium excretion by 130% (P <
0.01) from baseline value with accompanying 18% decrease (P < 0.05)
in PAH clearance (ERPF) without changing inulin clearance (GFR).
When compared to placebo infusion, ANF infusion caused a significant
increase in fractional excretion lithium (FELt), a marker of proximal
tubular function. Fractional distal delivery of sodium, another marker
of proximal tubular outflow as determined by free water clearance, was
also increased during ANF infusion. As expected, ANF decreased
distal nephron fractional sodium reabsorption as evaluated by both the
"lithium method" and by the conventional "solute-free water meth-
od." Prazosin on its own had no effect on blood pressure, renal function
or hormonal parameters. When given in combination with ANF,
prazosin blunted the natriuretic effect of ANF from 130% to 35% (P <
0.01). However, prazosin pretreatment did not influence the ANF-
induced fall in blood pressure or ERPF nor the ANF-induced suppres-
sion of plasma aldosterone. We have therefore found evidence to
support the hypothesis that at basal levels of sympathetic tone, the
natriuretic effect of ANF in man is dependent on an intact sympathetic
nervous system, since sympathetic blockade by prazosin blunts its
sodium excretory effects.
Much research activity has gone into examining the interac-
tion between atrial natriuretic factor (ANF) and the renin-
angiotensin-aldosterone system [1]. Less attention has been
directed towards studying the interaction between ANF and the
renal sympathetic nervous system. This is despite the fact that
the renal sympathetic nervous system is known to exert a major
influence on renal sodium excretion by acting at nearly all sites
within the nephron [2]. Recently, low frequency renal nerve
stimulation has been shown to blunt the natriuretic response to
ANF in anesthetized rats [3], although other similar experi-
ments have produced conflicting results [4, 5]. An alternative
proposition supported by experimental data is that ANF func-
tions as a neuromodulator, and that part of the mechanism of
action of ANF is to inhibit endogenous renal sympathetic nerve
activity [6—8].
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To date, most previous studies examining the interaction
between ANF and the renal sympathetic nervous system have
been in experimental animal models of renal nerve stimulation
or denervation which does not distinguish the level (pre- or
post-synaptic) or adrenoceptor subtype involved in ANF-in-
duced natriuresis [3—5]. In this regard, post-synaptic renal
alpha-l-adrenoceptors appear to have the major functional
influence in the kidney although, numerically, alpha-2-adreno-
ceptors are more abundant in the kidney [9]. The aim of this
study was to examine the effect of selective alpha-l-adrenocep-
tor blockade by prazosin.on the renal response to ANF in man.
Prazosin is a selective alpha-1-adrenoceptor blocker which does
not interfere with reflexes mediated via pre-synaptic alpha-2-
adrenoceptors [10]. A low dose prazosin was used to avoid any
effect on systemic blood pressure since this by itself would alter
sodium excretion.
Methods
Eight male volunteers aged 19 to 28 years (mean 23.8 years)
were studied. Normal health was established by medical his-
tory, physical examination, biochemical and hematological
screening, electrocardiogram and urinalysis. None were taking
any regular medication. All subjects gave written informed
consent to the study protocol, which had been approved by the
hospital committee on medical ethics.
Volunteers had a dietary history to ensure they were salt
replete and this was confirmea by pre-study timed urine collec-
tions. Each volunteer was asked to adhere to his normal diet for
the duration of the study and to maintain a similar pattern of
meals for the 24 to 48 hours prior to each investigation day. No
medication was permitted for the duration of the study.
Subjects were studied on four occasions, with at least one
week between each investigation day. All had fasted from 2200
hours the evening before and had abstained from alcohol over
the previous 36 hours. Cigarette smoking and caffeine-contain-
ing drinks were prohibited on the morning of the study. Each
volunteer had taken 500 mg of lithium carbonate 10 hours
before the start of the study. On attending the clinical labora-
tory at 0800 hours, subjects were seated and an intravenous
cannula was placed in each antecubital fossa for subsequent
infusion and blood sampling. At 0810 hours, priming doses of 50
mg/kg inulin (mutest, Laevosan Gessellschaft m.b.H., Linz,
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Austria) and 10 mg/kg para-aminohippurate (PAH) (Aminohip-
purate Sodium, Merck Sharpe & Dohme, Westpoint, Pennsyl-
vania, USA) were injected intravenously, followed by continu-
ous infusion of both drugs at doses calculated to achieve
steady-state plasma concentrations of 200 mg/liter and 25 mgI
liter, respectively.
At 0805 hours, a 20 mi/kg oral water load was administered
over a 15 minute period. Every 20 minutes thereafter, subjects
stood to void until the end of the study. The volume of urine
passed was measured and an aliquot stored for later analysis.
On each occasion an equal volume of water was given to drink.
In this way, a stable diuresis was established over a period of
approximately 1.5 hours at 1000 hours. The last 20 minute
collection period of this stabilization period was taken as
baseline. At 1000 hours, each subject received orally 0.25 mg of
prazosin (Hypovase, Pfizer Ltd., Sandwich, Kent, UK) or
placebo tablet. After two further 20-minute collection periods at
1040 hours, an infusion of either placebo (5% D-glucose) or
ANF 5 pmollkg/min [atnal natriuretic factor (99-126), Shire
Pharmaceuticals Ltd, Andover, Hampshire, UK] was com-
menced and continued for 60 minutes. The order of the infu-
sions was random and administered in a single blinded fashion.
The study terminated at 1220 hours so that there were two
further urine collections after withdrawal of the infusion. Heart
rate (HR) was displayed continuously on an ECG oscilloscope
(adult monitor 7835lA, Hewlett Packard, Boblingen, Germany)
and the blood pressure was measured every five minutes with a
semi-automatic sphygmomanometer (Dinamap Vital Signs
Monitor 1846, Critikon, Tampa, Florida, USA).
Urine samples were obtained at the end of all clearance
periods. Venous blood was collected at the midpoint of each
collection period into plain glass tubes (5 ml, no preservative)
for measurement of electrolytes, including lithium and osmolal-
ity, and into chilled tubes (10 ml, lithium heparin) for measure-
ment of plasma PAH and inulin. Venous blood was also
collected at the midpoint of the baseline clearance period and
the last clearance period during the ANF or placebo infusion for
measurement of plasma norepinephrine (2 ml, lithium heparin),
plasma angiotensin 11(10 ml, 0.05 M o-phenanthroline, 2 g of
neomycin/liter, 0.125 M EDTA disodium salt) and plasma
aldosterone (2 ml, lithium heparin). All samples were placed on
ice (except electrolytes which were allowed to clot), centrifuged
at 4°C and the plasma/serum separated off and stored at —20°C
(electrolytes, ANF, aldosterone, PAH, inulin) or —70°C (nor-
epinephrine) until assayed.
Analytical and statistical methods
All samples were measured together in one assay run, for any
given variable. Plasma norepinephrine was assayed by the
double isotope radio-enzymatic method [11]. The intra-assay
coefficient of variation (INCV) for this method in our laboratory
was 8.0% and the interassay coefficient of variation (ITCV) was
11.1%. Angiotensin II was measured, after plasma extraction,
by a radioimmunoassay kit (Immunodiagnostics, Washington,
Tyne and Wear, UK). The INCV and ITCV of this assay were
2.2% and 12.1%, respectively. Plasma aldosterone was also
measured by a commercially available radioimmunoassay kit
(Serono Diagnostics Ltd, Woking, Surrey, UK). The INCV and
ITCV for this method were 6.4% and 14%, respectively. Plasma
ANF was measured by RIA (Amersham International Ltd,
Amersham, Buckinghamshire, UK) after plasma extraction by
the method of Richards et al [121. The INCV and ITCV for this
method were 4.9% and 7.8%, respectively. Serum and urinary
sodium, and lithium were measured with an indirect reading ion
specific electrode (Beckmann System E2A, High Wycombe,
Buckinghamshire, UK). Plasma and urinary osmolalities were
measured by the freezing point depression method (Osmomat
030, Gonotec, Berlin, Germany). Urine and plasma inulin was
assayed spectropnotometrically (Pye Unicam SP9, Phillips,
Cambridge, UK) using resorcinol as the color reagent. The
INCV and ITCV for this assay in our laboratory was 1.1% and
2.9% for plasma and 1.0% and 3.6% for urine, respectively.
Urine and plasma PAH was also assayed spectrophotometri-
cally (Cobas Bio, Roche, Basle, Switzerland) using 4-dimethyl
amino benzyldehyde as the color reagent. The INCV and ITCV
were 2.1% and 2.0% for plasma, and 1.7% and 2.3% for urine.
The following indices were calculated according to standard
criteria. Clearance was calculated as UV/P, where U = urinary
concentration, V = urinary flow rate and P = plasma concen-
tration. Clearances of inulin (C1) and PAH (CPAH) were
employed to estimate glomerular filtration rate (GFR) and
effective renal plasma flow (ERPF), respectively. Fractional
excretion (fractional clearance; FE) was calculated as clearance
divided by C1.
Segmental tubular sodium handling was estimated from lith-
ium clearance 113]. Fractional excretion of lithium (FEL1), was
used as an estimate of the fraction of glomerular filtrate not
reabsorbed by the proximal tubule and delivered to the distal
nephron. Reabsorption of sodium in the distal nephron was
calculated from CL — CNa. Finally, fractional reabsorption of
distally delivered sodium was estimated from (CLlCNa)/CLI.
As an alternative method for estimating segmental sodium
handling, we used the CH,o and CNa as follows: (CNa +
CH2O)/GFR was used as an index of filtered sodium to the
diluting segment; and CH20/(CH2O + CNa) was used as an index
of fractional reabsorption of sodium delivered to the diluting
segment [14].
Statistical evaluation
For each parameter, the baseline value was taken to be the
last clearance period before the stabilization phase. All values
were expressed as means standard error. Comparison of
treatment groups (placebo, ANF alone, prazosin alone and the
combination of prazosin and ANF) on hemodynamic and renal
function parameter was assessed by repeated measures analysis
of variance (MANOVA, SPSS-plus). Hormonal responses were
compared with baseline values using the paired Student's t-test
following Bonferroni correction. A P value of less than 5% was
considered statistically significant.
Results
Pre-study screening showed that all subjects were salt replete
(24 hr sodium excretion was 168 23 mmol). There were no
significant differences in any of the baseline hemodynamic,
neuroendocrine and renal function parameters before adminis-
tration of the prazosin or placebo tablet (Tables 1 and 2).
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Table 1. Baseline hemodynamic and renal function parameters on all
four study days (N = 8)
Study day P + P PRZ + P P + ANF PRZ + ANF
GFR mI/mm 101 6 98 6 102 5 100 6
ERPF mI/mm 580 22 631 22 637 18 616 28
UNaV umol/min 161 18 167 15 171 10 175 22
FEL, % 27,8 1.1 30.3 2.1 26.1 2.0 27.5 1.8
(CLiCNa) % 95.7 0.5 95.9 0.5 95.1 0.2 95.1 0.3
(CNa±CH2O) % 14.1 1.8 15.6 1.6 12.9 1.1 15.5 1.9
(CH20) %
CM2O + CNa
91.4 0.9 91.7 0.6 90.3 0.5 90.7 0.9
Mean arterial pres- 90 2 92 2 91 2 90 3
sure mm Hg
Heart rate mm' 65 2 63 2 62 2 66 2
Values are mean SE. Abbreviations are: GRF, glomerular filtration
rate; ERPF, effective renal plasma flow; UNaV, urinary sodium excre-
tion; FELl, fractional excretion of lithium; (CLI — CNa)/CL,, fractional
reabsorption of distally delivered sodium; (CH2O + CNa)/GFR, sodium
delivery to the diluting segment; CH20/(CH2O + CN), fractional reab-
sorption of sodium delivered to the diluting segment; P, placebo tablet
or infusion of 5% D-glucose; PRZ, prazosin 0.25 mg; ANF, ANF 5
pmol/kg/min for 60 mm. Samples were taken at —10 mm before oral
doses of P or PRZ. ANF or P infusion was commenced at +40 mm after
oral doses of P or PRZ. None of the parameters was statistically
different between study days.
Effects of ANF and prazosin on blood pressure and heart
rate
Figure 1 shows the effect of ANF infusion on HR and mean
arterial BP. ANF infusion decreased mean arterial pressure (P
<0.05 vs. placebo by MANOVA) without having any effect on
HR. Figure 1 also confirmed that 0.25 mg prazosin administered
orally is a non-depressor dose and that it did not influence the
hemodynamic response to ANF.
Effects of ANF and prazosin on ERPF, GFR and UNaV
During ANF infusion, ERPF decreased by 18% from baseline
value (from 637 18 mi/mm to 520 37 mI/mm, P < 0.5 vs.
placebo; Fig. 2). Prazosin on its own did not influence ERPF
nor did it influence the ERPF response to ANF (a decrease of
19% from baseline, from 616 28 mllmin to 496 31 ml/min,
P < 0.05 vs. placebo). GFR did not change on any of the study
days (Fig. 2).
Urinary sodium excretion increased by approximately 130%
from baseline value (from 171 10 prnol/min to 392 48
mol/min, P < 0.01 vs. placebo) during ANF infusion. Prazosin
pretreatment blunted this response to a maximal increase of
only 35% from baseline value (from 175 22 mol/min, to 237
31 mol/min, P < 0.01 vs. placebo + ANF study day).
Effects of ANF and prazosin on segmental tubular sodium
handling
Segmental tubular sodium handling was estimated from data
derived from lithium clearance. ANF alone increased FELl by
38% from baseline value (from 26.1 2.0% to 36.0 4.2%, P
<0.05 vs. placebo). On the prazosin + ANF study day, there
was blunting of the ANF induced rise in FELl with only a
maximal rise of 15%from baseline value (from 27.5 1.8% to
30.5 2.0%). Fractional reabsorption of distally delivered
sodium [(CLI — CNa)/CLi} was decreased by ANF (from 95.1
0.2% to 91.1 0.1%, P < 0.01 vs. baseline) and this decrease
was also blunted by prazosin pretreatment (P < 0.05 vs.
placebo + ANF study day; Figs. 3 and 4).
Segmental tubular sodium handling was also estimated by use
of the alternative "solute-free water method" (Figs. 3 and 4).
These results concur with those obtained with the "lithium
method".
Effects of ANF and prazosin on neuroendocrine parameters
ANF infusion caused comparable and significant increases in
circulating ANF on the placebo + ANF and prazosin + ANF
study days (Table 2). Prazosin on its own did not cause any
hormonal changes. ANF infusion caused a significant fall in
plasma aldosterone levels and prazosin pre-treatment did not
influence these changes (Table 2). There were no significant
changes in plasma angiotensin II on all four study days. Despite
the significant fall in mean arterial pressure during ANF infu-
sion, plasma norepinephrine remained unchanged. Plasma nor-
epinephrine was also unaltered on the prazosin + ANF study
day.
Discussion
This study has two main findings. Firstly, we have shown that
a pharmacological dose of ANF in man was associated with a
marked natriuresis and a fall in blood pressure which was not
accompanied by a reflex tachycardia nor an augmentation of
plasma norepinephrine. The lack of a reflex increase in heart
rate and plasma norepinephrine despite a fall in blood pressure
lends support to the notion that ANF may have a modulatory
effect on the sympathetic nervous system. Secondly, our study
showed that alpha- 1 -adrenoceptor blockade by a non-depressor
dose of prazosin markedly blunts the renal response to ANF in
man. Our results would suggest that the natriuretic effect of
ANF in resting man is partly dependent on some intrinsic
sympathetic tone since sympathetic blockade blunts its sodium
excretory effects. This hypothesis is, however, dependent upon
the assumption that the dose of prazosin used in this study
results in blockade of the renal sympathetic nervous system. It
could be argued that prazosin may have caused a fall in blood
pressure and therefore secondarily activate rather than block
the renal sympathetic nervous system. It could also be argued
that ANF may decrease cardiac preload and consequently
lower atrial filling pressures which would then increase renal
sympathetic nerve activity. However, the dose of prazosin
chosen in this study was such that blood pressure was not
affected by prazosin, nor was there evidence of any changes in
atrial filling pressures since plasma ANF was not affected by
prazosin treatment. While we did not measure urinary norepi-
nephrine, both heart rate and plasma norepinephrine were
unchanged by prazosin, which suggests that prazosin did not
secondarily activate the sympathetic nervous system. Our
results are consistent with recent reports [6—81 that part of
ANF's action is to function as a neuromodulator of sympathetic
nervous function, and that in the kidney ANF may act by
decreasing renal sympathetic nerve activity, which then facili-
tates the diuretic and natriuretic effects of AMP.
There is now cumulative evidence to suggest that ANF may
behave as a neuromodulator of autonomic nervous function
[reviewed in 15]. Ackermann et a! [16] found that intravenous
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Table 2. Neuroendocnne parameters on all four study days (N = 8)
Study day P + P PRZ + P P + ANF PRZ +ANP
ANF pmol/liter
Baseline (—10 mm)
End of infusion (+90 mm)
Angiotensin II pmol/liter
Baseline (—10 mm)
End of infusion (+90 mm)
Aldosterone pmol/liter
Baseline (—10 mm)
End of infusion +90 mm
Norepinephrine nmol/liter
Baseline (—10 mm)
End of infusion (+90 mm)
6.1 0.6
5.8 0.8
32.1 3.7
34.2 3.5
426 17
432 13
2.93 0.41
3.15 0.49
6.5 0.8
6.6 1.2
33.7 5.2
34.4 4.8
416 14
443 27
3.13 0.38
3.26 0.35
7.0 1.2
67.2 12.7a
38.2 9.3
35.6 8.0
429 13
288 12
2.77 0.39
2,90 0.43
6.5 1.8
70.9 99a
36.2 3.1
33.5 3.8
421 20
275 14
3.16 0.37
3.45 0.64
Results are mean SE. Abbreviations are: P. placebo tablet or infusion of 5% D-glucose; PRZ, prazosin 0.25 mg; ANF, ANF 5 pmol/kg/mmn for
60 mm. Samples were taken at —10 mm (before oral doses of P or PRZ at 0 mm) and at +90 mm (10 mm before the end of P or ANF infusion).
The P or ANF infusion was commenced at +40 mm.
a P < 0.01 vs. baseline by paired Student's f-test
NSP+P PRZ+P
t 4. t 4 t 4 I
administration of atnal extracts to rats caused a reduction in
arterial blood pressure, which was accompanied by a decrease
in heart rate rather than by the expected baroreceptor-mediated
reflex tachycardja. Thoren et a! [6] went on to show that
atriopeptins (II and III) decreased renal nerve activity in sino
aortic-denervated rats and that this effect was eliminated by
vagotomy but not by atropine, which suggests that the effects of
vagotomy were related to interruption of vagal afferents but not
vagal efferents. Schultz et al [7] have recently confirmed this
when they showed that blockade of afferent vagal C fibers
abolishes the inhibition of renal sympathetic nerve activity
produced by ANF. These authors suggested that ANF stimu-
lated vagal afferent endings to produce an inhibitory effect on
sympathetic outflow. These observations, in conjunction with
our findings, would support a potential role for ANF in modu-
lating autonomic nervous function, a role that could serve to
amplify or facilitate the peripheral hormonal action of ANF on
vascular and renal structures.
Several theories on the mechanism of action of this neuro-
modulatory effect of ANF have been postulated, including an
effect on the baroreceptor reflex mechanism as well as an effect
on peripheral noradrenergic neurotransmission [8]. Takeshita et
al [17] have found that ANF 30 gIkgImin attenuated the reflex
increase in forearm vascular resistance during cardiopulmonary
baroreceptor activation by lower body negative pressure in
man, an observation which has since been confirmed by others
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FIg. 1. Heart rate, min' (HR) and mean arterial pressure (MAP), mm Hg on all 4 study days (N = 8). Abbreviations are: P, placebo tablet or
5% D-glucose, ANF, atrial natnuretic factor (99-126) 5 pmol/kglmin; and PRZ, prazosin 0.25 orally. Horizontal and vertical arrows at bottom of
figure indicate timing of P/ANF infusion and P/PRZ dosing, respectively. < 0.05 vs P by MANOVA. MAP decreased significantly (P < 0.05
versus P) on both P + ANFand PRZ + ANF study days. MAP responses did not differ between P + ANF and PRZ + ANF study days. HR did
not differ between all 4 study days.
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Fig. 2. Effective renal plasma flow, mi/mm (ERPF), glomerular filtration rate, mi/mm (GFR) and absolute urinary sodium excretion, p.mollmin
(UNV) on all 4 study days (N = 8). Abbreviations are: P, placebo tablet or 5% D-glucose; ANF, atrial natriuretic factor (99-126) 5 pmollkglmin;
and PRZ, prazosin 0.25 mg orally. Horizontal and vertical arrows at bottom of figure indicate timing of P/ANF infusion and P/PRZ dosing,
respectively. *D <0.05, **p < 0.01 vs. P by MANOVA. a denotes statistical significance (P < 0.05 by MANOVA) of the difference between ANF
+ P study day and ANF + PRZ study day.
[18, 19]. The mechanism(s) of ANF's influences on barorecep-
tor reflexes are unknown, although it has previously been
suggested that ANF may act centrally to suppress sympathetic
nervous activity [20, 21]. However, there is animal evidence to
suggest that ANF may also act by inhibiting peripheral norad-
renergic neurotransmission. Sasaki et al [22] have shown that
ANF-induced reduction in blood pressure was decreased by
sympathectomy, which suggests that sympathetic nerves might
be involved in the hypotensive action of ANF. Studies by
Koepke et al [23, 24] showed that graded doses of synthetic
ANF infused into conscious normal rats produced dose-depen-
dent decreases in renal sympathetic nerve activity in associa-
tion with diuresis, natriuresis and hypotension. More recently
Holtz, Sommer and Bassenge [25] have also reported a sup-
pression of epinephrine release rate during ANF infusion in
conscious dogs and an absence of reflex tachycardia or aug-
mentation of norepinephrine release in response to ANF-
induced hypotension. Likewise, in this study, we found that
ANF-induced hypotension was not associated by reflex sympa-
thetic nervous activation in man as indicated by the lack of
change in heart rate or plasma norepinephrine. Furthermore,
we have also shown that prazosin blunted the natriuretic
(although not the hypotensive) effect of ANF in man. This
would suggest that the natriuretic effect of ANF in man is
dependent on an intact renal sympathetic nervous system. It
could be argued that in this study, alpha-l-adrenoceptors block-
ade by prazosin removed the sympathetic neuromodulator
component of ANF's renal action, thereby blunting its natri-
uretic effect.
However, not all previous data appear to agree with ours,
although on closer inspection, it turns out that the level of
sympathetic nervous system activity is an important determi-
nant. In fact, an activated level of renal sympathetic nervous
system activity appears to limit the renal effects of ANF [3]
whereas in basal conditions, as we have found here, an intact
intrinsic sympathetic nervous system is required to maintain
ANF's natriuretic effects. Indeed, we have previously found
that in a similar study to this one, exogenously infused norepi-
nephrine (to mimic an activated sympathetic nervous system)
was found to blunt the natriuretic effect of ANF in normal man
[261. In other states with an activated sympathetic nervous
system, such as nephrotic or cirrhotic rats, renal denervation
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Fig. 3. Segmental tubular sodium handling as determined by the "lithium clearance" technique on all four study days (N = 8). Abbreviations are:
FeLt, fractional excretion of lithium which estimates the fractional delivery of glomerular filtrate to distal nephron; (CLi — CNa)ICLj, fractional
reabsorption of distally delivered sodium; P, placebo tablet or 5% D-glucose; ANF, atrial natriuretic factor (99-126) 5 pmol/kg/min; and PRZ,
prazosin 0.25 ng orally. Horizontal and vertical arrows at bottom of figure indicate timing of P/ANF infusion and P/PRZ dosing, respectively. *P
<0.05 and ** < 0.01 vs. P by MANOVA. a denotes statistical significance (P < 0.05 by MANOVA) of the difference between ANF + P study
day and ANF + PRZ study.
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Fig. 4. Segmented tubular sodium handling as determined by the solute-free water method on all four study days (N = 8). Abbreviations are:
(CH2O + CNa)/GFR, fractional sodium delivery to the diluting segment; CHO/(CH20 + CNJ, fractional reabsorption of sodium delivered to the
diluting segment; P, placebo tablet or 5% D-glucose; ANF, atrial natriuretic factor (99-126) 5 pmol/kg/min; and PRZ, prazosin 0.25 mg orally.
Horizontal and vertical arrows at bottom of figure indicate timing of ANF infusion and PRZ dosing, respectively. * <0.05 and **<0.01 versus
P by MANOVA. a denotes statistical significance (P < 0.05 by MANOVA) of the difference between ANF + P study day and ANF + PRZ study
day.
was found to restore the natriuretic response to ANF [23, 241.
Along similar lines, clonidine, an alpha-2-adrenoceptor agonist
which decreases presynaptic norepinephrine release has been
shown to restore the originally blunted renal response to ANF
in congestive heart failure rats [27].
The reason for conflicting results in the literature could,
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however, be due to other factors. We were careful in this
experiment to use a dose of prazosin which did not alter
systemic blood pressure since this by itself would alter sodium
excretion. Some of the previous conflicting results may have
been related to changes in systemic blood pressure and hence
renal perfusion pressure. Another variable in these experiments
relates to renal alpha-2- or beta-adrenoceptors. In our experi-
ment we used prazosin and therefore produced only selective
postsynaptic alpha-I -adrenoceptors blockade, whereas other
experimental techniques, particularly renal denervation, would
have effectively inhibited alpha-2- and/or beta-adrenoceptors.
Renal alpha-i -adrenoceptors appear to have the major func-
tional influence in the kidney, although numerically alpha-2-
adrenoceptors are more abundant [9].
The site of this interaction between the renal sympathetic
nervous system and ANF is unclear. The renal sympathetic
nervous system is known to affect the excretion of sodium by
acting at various levels of nephron function [2]. Our results do
not support an interplay at the glomerulovascular level, since
we did not observe any changes in GFR and prazosin did not
alter the ANF-induced fall in ERPF. This ANF-induced fall in
ERPF, as measured by clearance technique, has generally been
reported in man [28—30], although the underlying mechanism(s)
for this is unclear. It may be due to a direct efferent arteriolar
constriction or perhaps to subtle changes in mesangial cell
interstitial pressure which will compress postglomeruiar blood
vessels [reviewed in 31]. While prazosin did not alter ANF's
effects on ERPF, it did interfere with the tubular effects of ANF
as determined by both lithium clearance and "solute-free wa-
ter" clearance techniques. It is unclear whether this interaction
at the tubular level is via a direct tubular interaction or
indirectly via changes in intrarenal hemodynamics, including
alteration in medullo-papillary hemodynamics. In this study, we
found that a pharmacological dose of ANF increases FELT, thus
suggesting that whole kidney proximal tubular fractional reab-
sorption of sodium is inhibited by ANF. We also found a
significant increase in fractional distal delivery, an independent
marker of proximal outflow based on the generation of free
water. The finding of a similar change in these two separate
markers of proximal tubular outflow, measured in parallel,
suggests that we have observed a genuine effect. Although
similar observations have been reported in both experimental
animals and man [32—36], others have found a lack of proximal
tubular outflow [37—39]. Since ANF receptors have not been
identified in the proximal tubules [40], it has been suggested the
mechanism of these proximal tubular effects of ANF if demon-
strated is probably an indirect one [36]. Possible indirect
mechanisms include the inhibition of angiotensin II by ANF or
an alteration in intrarenal hemodynamics as well as pertubation
of peritubular Starling's forces by ANF. In this study, prazosin
pretreatment blunted these proximal tubular effects of ANF in
man without altering plasma angiotensin II. This influence of
prazosin of proximal tubular function (although only apparent
during ANF infusion in this study) is in keeping with the
presence of proximal tubular adrenergic receptors and demon-
strates that synaptically released norepinephrine increases
proximal tubular sodium reabsorption [2, 9]. Since prazosin did
not alter plasma norepinephrine nor angiotensin II, it is there-
fore possible that prazosin might have caused undetected
changes in intrarenal hemodynamics thereby off-setting ANF's
indirect actions on the proximal tubules. Obviously any evi-
dence for this action in man must remain speculative and cannot
be directly inferred from this study.
We also found that ANF inhibited fractional distal sodium
reabsorption as measured by the "solute free water" method
and the "lithium clearance" technique. This is in agreement
with a large body of animal evidence which has suggested a
major portion of action of ANF may be due to a distal nephron
effect especially within the collecting duct system [32, 33, 41].
Prazosin was shown in this study to markedly blunt the distal
tubular effects of ANF as determined by clearance techniques.
However, it is worth noting that both the lithium clearance and
"solute-free water" clearance techniques have their limita-
tions. Use of the lithium clearance technique gives useful data
on the tubular sodium handling in man [13], but its interpreta-
tion may sometimes be difficult. For instance, recent evidence
suggests that lithium handling may also occur beyond the
proximal tubule, within the loop of Henle [31, 42, 43]. As such,
one must take this into account when interpreting lithium
clearance data. This is especially relevant in this study since
reabsorption at the loop of Henle may be affected by both renal
sympathetic nerves [44] and also by ANF [45, 46]. While the
loop of Henle may be a possible site of interaction between
prazosin and ANF, one cannot exclude an interaction at both
the proximal and distal tubules (distal tubule proper and col-
lecting ducts) where alpha-adrenoceptors are present [2, 9], and
where ANF has been shown to have an effect [3 1—34]. Given the
limitations of clearance techniques, it is difficult to state the
exact location of the interaction between prazosin and ANF,
although the evidence in this study suggests that it is at the
tubular level. Clearly further studies are required to examine
the exact location of this interaction between ANF and the
sympathetic nervous system in the kidney.
In this study, ANF treatment decreased plasma levels of
aldosterone. This inhibitory effect of ANF on aldosterone
secretion has been previously described in man, and may result
partly from a decrease in plasma renin activity and/or a direct
action on aldosterone secretion in the adrenal gland [reviewed
in 1]. In this study, there was no significant change in plasma
angiotensin II, although it is likely that the our measurement of
plasma angiotensin II does not adequately reflect the small
changes in renin secretion rate. Prazosin treatment alone was
not accompanied by any changes in plasma levels of angiotensin
II and aldosterone, nor did it affect the ANF-induced fall in
plasma aldosterone.
In summary our results have shown that a pharmacological
dose of ANF in man was associated with a marked natriuresis,
and a fall in blood pressure which was not accompanied by a
reflex activation of the sympathetic nervous system. We have
also shown that a non-depressor dose of prazosin caused a
significant reduction in ANF's effects on tubular sodium excre-
tion in man without any alteration by prazosin of ANF's effects
on systemic blood pressure, renal blood flow and the renin-
angiotensin-aldosterone system. We have, therefore, found
evidence to support the hypothesis that at basal levels of
sympathetic tone, the natriuretic effect of ANF is dependent on
some intrinsic sympathetic tone, in particular, renal alpha-i-
adrenoceptor activity at the renal tubules.
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